Earnings Call Summary | MDxHealth(MDXH.US) Q4 2023 Earnings Conference
Earnings Call Summary | MDxHealth(MDXH.US) Q4 2023 Earnings Conference
The following is a summary of the MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript:
以下是MDxHealth SA（MDXH）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
MDxHealth reported a Q4 revenue of $19.4 million, a 50% increase compared to Q4 2022, and the full-year revenue was $70.2 million, an 89% increase year-over-year.
Gross profit for Q4 was $12.7 million, a 75% increase from Q3 2022, with gross margins improving to 65.3% from 56% in Q4 2022. Similarly, for FY 2023, the gross profit was $43.9 million with an improved gross margin of 62.6%.
The company managed to reduce its operating loss for Q4 to $6.3 million, a 30% reduction compared to the previous year, and the full-year operating loss was reduced 28% to $27.3 million.
Cash equivalents by the end of 2023 were $22.4 million, and the company projects a revenue between $79 million and $81 million for 2024.
MDxHealth報告稱，第四季度收入爲1,940萬美元，與2022年第四季度相比增長了50％，全年收入爲7,020萬美元，同比增長89％。
第四季度的毛利爲1,270萬美元，比2022年第三季度增長75％，毛利率從2022年第四季度的56％提高到65.3％。同樣，2023財年的毛利爲4,390萬美元，毛利率提高了62.6％。
該公司設法將第四季度的營業虧損減少至630萬美元，與去年同期相比下降了30％，全年營業虧損減少了28％，至2730萬美元。
到2023年底，現金等價物爲2,240萬美元，該公司預計2024年的收入在7,900萬美元至8100萬美元之間。
Business Progress:
業務進展：
MDxHealth successfully expanded their test menu, establishing cross-selling of complementary diagnostic solutions, and broadened payer coverage.
Over the last 18 months, the company grew its offering from one to four revenue-generating tests and all of their prostate cancer tests are now covered by Medicare.
The company is considering various inbound opportunities for partnerships, mergers, acquisitions, and distribution.
Additionally, the company plans to expand into the sector of patient monitoring for those on annual active surveillance with their Monitor project.
The company will continue to focus on controlling costs, keeping operating expenses at bay while ensuring sustainable growth.
MDxHealth成功擴展了他們的測試菜單，建立了互補診斷解決方案的交叉銷售，並擴大了付款人的覆蓋範圍。
在過去的18個月中，該公司提供的創收測試從一項增加到四項，並且他們所有的前列腺癌檢查現在都由Medicare承保。
該公司正在考慮各種入境機會，包括合作、合併、收購和分銷。
此外，該公司計劃通過其Monitor項目將年度積極監測對象擴展到患者監測領域。
該公司將繼續專注於控制成本，控制運營開支，同時確保可持續增長。
More details: MDxHealth IR
更多詳情： MDxHealth I
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。